Red Flags Detected

• ⚠ Going Concern (new) — The company explicitly states substantial doubt about its ability to continue as a going concern due to recurring losses and net capital deficiency.
• ⚠ No Patents or Pending Applications (new) — The company has no patents or pending patent applications for its core products, relying solely on trade secrets and know-how, which exposes it to competitive risks.
• ⚠ U.s. Market Access Restricted (new) — The company cannot sell its products in the U.S. because psilocybin and MDMA are Schedule I controlled substances, significantly limiting its addressable market.
• ⚠ Selling Shareholder Dilution (new) — The sale or issuance of common shares to the Selling Shareholder will likely cause dilution, and the potential sale of those shares could depress the stock price.
• ⚠ Auditor Change With Going Concern Qualification (new) — The prior auditor's report for fiscal 2023 contained a going concern qualification, and the company changed auditors in November 2024.